Neoantigen Vaccines Pass the Immunogenicity Test.

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Neoantigens are derived from tumor-specific genomic alterations.
• These neoantigens represent a novel class of targets for cancer immunotherapy.
• Precision therapies are being developed based on individual tumor mutational profiles.

Purpose of the Study:

• To highlight neoantigens as targets for cancer immunotherapy.
• To discuss the potential of neoantigen-based vaccines for precision therapies.

Main Methods:

• Review of recent reports on neoantigen vaccine platforms.
• Analysis of tumor mutational profiles for neoantigen identification.

Main Results:

• Neoantigens are authentic non-self antigens arising from tumor mutations.
• Various vaccine platforms targeting neoantigens have been reported.
• These platforms suggest a basis for customized precision therapies.

Conclusions:

• Neoantigens represent a promising new class of targets in cancer immunotherapy.
• Personalized neoantigen vaccines offer a path towards precision cancer medicine.